Sillajen explains Pexa-Vec trial failure – it was the rescue medsSouth Korean biotech Sillajen was hit hard last week when its oncolytic virus therapy Pexa-Vec failed a phase Share XSillajen explains Pexa-Vec trial failure – it was the rescue medshttps://pharmaphorum.com/news/sillajen-explains-pexa-vec-trial-failure-it-was-the-rescue-meds/
BMS has another Opdivo setback after liver cancer trial failureBristol-Myers Squibb’s cancer immunotherapy Opdivo has suffered another setback after it failed to improve on standard care in Share XBMS has another Opdivo setback after liver cancer trial failurehttps://pharmaphorum.com/news/bms-has-another-opdivo-setback-after-liver-cancer-trial-failure/
Oncology round-up: AZ and Daiichi score key trial win with breast cancer antibody and moreAZ and Daiichi Sankyo announced positive top-line results from the pivotal phase 2 DESTINY-Breast01 trial of trastuzumab deruxtecan, Share XOncology round-up: AZ and Daiichi score key trial win with breast cancer antibody and morehttps://pharmaphorum.com/views-and-analysis/oncology-round-up-az-and-daiichi-score-key-trial-win-with-breast-cancer-antibody-and-more/
Lilly gets fifth use for Cyramza with FDA liver cancer nodEli Lilly’s Cyramza has a new string to its bow after the FDA approved it as a second-line Share XLilly gets fifth use for Cyramza with FDA liver cancer nodhttps://pharmaphorum.com/news/lilly-gets-fifth-use-for-cyramza-with-fda-liver-cancer-nod/
Exelixis’ Cabometyx approved in second-line liver cancer in USExelixis’ cancer drug Cabometyx has been approved in a new liver cancer use in the US, providing a Share XExelixis’ Cabometyx approved in second-line liver cancer in UShttps://pharmaphorum.com/news/exelixis-cabometyx-approved-in-second-line-liver-cancer-in-us/
Ipsen warns over medicine supplies amid Brexit uncertaintyFrance’s Ipsen has become the latest pharma company to warn about the impact of Brexit on the pharma Share XIpsen warns over medicine supplies amid Brexit uncertaintyhttps://pharmaphorum.com/news/ipsen-warns-over-medicine-supplies-amid-brexit-uncertainty/
AZ begins liver cancer immunotherapy tie-up with AVEOAstraZeneca has announced a collaboration with US biotech AVEO oncology to investigate a potential cancer immunotherapy combination in Share XAZ begins liver cancer immunotherapy tie-up with AVEOhttps://pharmaphorum.com/news/az-begins-liver-cancer-immunotherapy-tie-up-with-aveo/
Merck gets FDA okay for Keytruda as liver cancer therapyMerck & Co/MSD has won approval in the US for PD-1 inhibitor Keytruda as a treatment for hepatocellular Share XMerck gets FDA okay for Keytruda as liver cancer therapyhttps://pharmaphorum.com/news/merck-gets-fda-okay-for-keytruda-as-liver-cancer-therapy/
EU regulators back Ipsen cancer drug in new liver cancer useIpsen’s bid to build a cancer franchise around its Cabometyx (cabozantinib) is gathering pace after European regulators backed Share XEU regulators back Ipsen cancer drug in new liver cancer usehttps://pharmaphorum.com/news/eu-regulators-cabometyx-liver/
